Have a feature idea you'd love to see implemented?
Let us know!
VRTX Vertex Pharmaceuticals Inc
Price (delayed)
$450.37
Market cap
$115.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.85
Enterprise value
$112.45B
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather
Highlights
VRTX's revenue is up by 10% YoY and by 2.8% QoQ
The gross profit has grown by 8% YoY and by 2.4% from the previous quarter
Vertex Pharmaceuticals's net income has shrunk by 114% YoY but it has increased by 2.1% QoQ
The EPS has dropped by 114% year-on-year but it has increased by 2.1% since the previous quarter
VRTX's debt has soared by 129% YoY and by 82% QoQ
Vertex Pharmaceuticals's quick ratio has decreased by 44% YoY
Key stats
What are the main financial stats of VRTX
Market
Valuations
Earnings
Shares outstanding
257.53M
Market cap
$115.98B
Enterprise value
$112.45B
Price to book (P/B)
7.44
Price to sales (P/S)
10.94
EV/EBIT
377.34
EV/EBITDA
217.21
EV/Sales
10.58
Revenue
$10.63B
EBIT
$298M
EBITDA
$517.7M
Free cash flow
-$1.11B
Per share
Balance sheet
Liquidity
EPS
-$1.85
Free cash flow per share
-$4.29
Book value per share
$60.56
Revenue per share
$41.19
TBVPS
$78.76
Total assets
$22.24B
Total liabilities
$6.61B
Debt
$1.7B
Equity
$15.63B
Working capital
$5.83B
Debt to equity
0.11
Current ratio
2.47
Quick ratio
2.08
Net debt/EBITDA
-6.83
Margins
Efficiency
Dividend
EBITDA margin
4.9%
Gross margin
86.1%
Net margin
-4.5%
Operating margin
-3%
Return on assets
-2.2%
Return on equity
-2.9%
Return on invested capital
2.9%
Return on capital employed
1.6%
Return on sales
2.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VRTX stock price
How has the Vertex Pharmaceuticals stock price performed over time
Intraday
-0.19%
1 week
-6.94%
1 month
-5.8%
1 year
26.94%
YTD
10.69%
QTD
-3.16%
Financial performance
How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$10.63B
Gross profit
$9.15B
Operating income
-$320M
Net income
-$479.8M
Gross margin
86.1%
Net margin
-4.5%
Vertex Pharmaceuticals's net income has shrunk by 114% YoY but it has increased by 2.1% QoQ
VRTX's net margin has shrunk by 113% YoY but it is up by 4.3% QoQ
The operating income has dropped by 108% year-on-year but it has grown by 19% since the previous quarter
The operating margin has shrunk by 107% YoY but it has increased by 21% QoQ
Growth
What is Vertex Pharmaceuticals's growth rate over time
Valuation
What is Vertex Pharmaceuticals stock price valuation
P/E
N/A
P/B
7.44
P/S
10.94
EV/EBIT
377.34
EV/EBITDA
217.21
EV/Sales
10.58
The EPS has dropped by 114% year-on-year but it has increased by 2.1% since the previous quarter
The stock's price to book (P/B) is 11% more than its 5-year quarterly average of 6.7 and 8% more than its last 4 quarters average of 6.9
The equity has grown by 6% from the previous quarter but it has contracted by 5% YoY
The price to sales (P/S) is 11% more than the 5-year quarterly average of 9.9
VRTX's revenue is up by 10% YoY and by 2.8% QoQ
Efficiency
How efficient is Vertex Pharmaceuticals business performance
The return on equity has dropped by 113% year-on-year
VRTX's return on assets has dropped by 113% year-on-year
The return on invested capital has dropped by 96% year-on-year and by 3.3% since the previous quarter
The return on sales has dropped by 94% year-on-year but it has increased by 12% since the previous quarter
Dividends
What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VRTX.
Financial health
How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's quick ratio has decreased by 44% YoY
Vertex Pharmaceuticals's current ratio has decreased by 39% YoY
VRTX's debt is 89% lower than its equity
VRTX's debt has soared by 129% YoY and by 82% QoQ
The debt to equity has soared by 120% YoY and by 83% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.